PFND logo

Pathfinder Cell Therapy OTCPK:PFND Stock Report

Last Price

US$0.000001

Market Cap

US$667.0

7D

0%

1Y

n/a

Updated

26 Mar, 2024

Data

Company Financials

Pathfinder Cell Therapy, Inc.

OTCPK:PFND Stock Report

Market Cap: US$667.0

PFND Stock Overview

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage.

PFND fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Pathfinder Cell Therapy, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pathfinder Cell Therapy
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$0.000001
52 Week LowUS$0.000001
Beta0
1 Month Changen/a
3 Month Changen/a
1 Year Changen/a
3 Year Change-99.99%
5 Year Change-99.97%
Change since IPO-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

PFNDUS BiotechsUS Market
7D0%-0.5%0.6%
1Yn/a9.6%29.5%

Return vs Industry: Insufficient data to determine how PFND performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how PFND performed against the US Market.

Price Volatility

Is PFND's price volatile compared to industry and market?
PFND volatility
PFND Average Weekly Movementn/a
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: PFND has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine PFND's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008n/aRick Franklinhttps://www.pathfindercelltherapy.com

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Pathfinder Cell Therapy, Inc. Fundamentals Summary

How do Pathfinder Cell Therapy's earnings and revenue compare to its market cap?
PFND fundamental statistics
Market capUS$667.00
Earnings (TTM)-US$1.08m
Revenue (TTM)n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PFND income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$1.08m
Earnings-US$1.08m

Last Reported Earnings

Sep 30, 2015

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did PFND perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.